Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

US FDA Continues Shift From Companion To Complementary PD-L1 Diagnostics With AstraZeneca Imfinzi Approval

May 03 2017

• By Bridget Silverman

Companion Diagnostics

Related Content

Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar

Apr 24 2017

Rydapt And Alunbrig Approvals Headline Good Week For Targeted Oncologics At US FDA

Apr 29 2017

US FDA Shows Relaxed Approach On Personalized Medicine In Zejula Approval

Mar 30 2017

AstraZeneca's Imfinzi Debuts In Bladder Cancer With Combo Coming Soon

May 01 2017

Related Companies

AstraZeneca PLC

Roche Holding AG

Bristol Myers Squibb Company

Merck & Co., Inc.

Agilent Technologies, Inc.

Novartis AG

Tesaro, Inc.

Merck KGaA

Pfizer Inc.

Additional Topics

Approvals Research & Development FDA In Vitro Diagnostics BioPharmaceutical

More from In Vitro Diagnostics

More from Diagnostics

Twitter feed RSS feed RSS feed

About

About UsOpens in new window
Meet the Team
AdvertiseOpens in new window
Contact Us

Account

My Account
My View
Email Preferences
Start Free TrialOpens in new window

More

Medtech Top 100 Ranking
Data Trackers
FDA Warning Letters

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window